This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

KEYTRUDA® (pembrolizumab) KEYNOTE-522 clinical data presentation

What would your treatment plan be for a newly diagnosed patient with high-risk early-stage triple-negative breast cancer (TNBC)?

KEYTRUDA, in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, is indicated for the treatment of adults with locally advanced, or early-stage triple-negative breast cancer at high risk of recurrence.1

Access the KEYNOTE-522 clinical data presentation.

More information about KEYTRUDA® (pembrolizumab) in triple-negative breast cancer (TNBC)

Reference

  1. KEYTRUDA Summary of Product Characteristics

Supporting documentation

By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website

GB-PDO-02101 | Date of Preparation: June 2022